RTP Mobile Logo
Oncology Grand Rounds Series: Part 9 — Chimeric Antigen Receptor T-Cell Therapy (Webinar Video Proceedings)
Released August 2020

Proceedings from the ninth in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Dr Krishna Komanduri, Dr Nikhil C Munshi, Dr Sattva S Neelapu, Dr Tiffany Richards and Ms Elizabeth Zerante. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hematologic cancers.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE (NCPD) activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with hematologic cancers.

    LEARNING OBJECTIVES

    • Develop an understanding of the biologic rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences between commercially available and investigational products.
    • Appraise existing and emerging efficacy data from clinical trials of approved and investigational CAR T-cell therapies directed at CD19 for relapsed/refractory B-cell lymphomas, and use this information to identify patients who may be candidates for this approach.
    • Understand how CAR T-cell therapies have been evaluated for acute lymphoblastic leukemia, and consider how approved platforms may be appropriately integrated into patient care.
    • Appreciate available data documenting the activity of CAR T-cell therapy directed against B-cell maturation antigen, and apply this knowledge to identify patients with multiple myeloma who may be appropriate for this approach as part of a clinical trial.
    • Recognize common adverse events associated with approved and investigational CAR T-cell therapies, and implement strategies to educate patients eligible for this treatment about the potential for these complications.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENTS
    Audio Program: This educational activity for 2 contact hours is provided by RTP during the period of August 2020 through August 2021.

    This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 1.5 contact hours is provided by RTP during the period of August 2020 through August 2021.

    This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/Meetings/ONS2020/CART/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for CNE (NCPD) accreditation. CNE (NCPD) programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE (NCPD) provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the mp3s, review the downloadable slide sets, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCART2020/CNE. The corresponding video program is available as an alternative at ResearchToPractice.com/ONSCART2020/Video.

    Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCART2020/Video/CNE. The corresponding audio program is available as an alternative at ResearchToPractice.com/ONSCART2020.

    This is a video CNE (NCPD) program. To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCART2020/Video/CNE.

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Krishna Komanduri, MD
    Sylvester Comprehensive Cancer Center
    Miller School of Medicine
    University of Miami Health System
    Miami, Florida

    Advisory Committee: Kiadis Pharma; Consulting Agreements: Autolus Therapeutics, Celgene Corporation, Helocyte Inc, Incyte Corporation, Kadmon, Kite, A Gilead Company, Novartis, Takeda Oncology; Contracted Research: Autolus Therapeutics, Celgene Corporation, Incyte Corporation, Kite, A Gilead Company, Novartis.

    Nikhil C Munshi, MD
    Kraft Family Chair
    Director of Basic and Correlative Science
    Jerome Lipper Multiple Myeloma Center
    Professor of Medicine
    Harvard Medical School
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, BeiGene, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, OncoPep, Takeda Oncology; Ownership Interest: OncoPep.

    Sattva S Neelapu, MD
    Professor and Deputy Chair
    Department of Lymphoma and Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee and Consulting Agreements: Adicet Bio, Allogene Therapeutics, Celgene Corporation, Incyte Corporation, Kite, A Gilead Company, Kuur Therapeutics, Legend Biotech, Merck, Novartis, Pfizer Inc, Precision BioSciences, Unum Therapeutics; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Allogene Therapeutics, Bristol-Myers Squibb Company, Cellectis, Karus Therapeutics, Kite, A Gilead Company, Merck, Poseida Therapeutics, Precision BioSciences, Unum Therapeutics.

    Tiffany Richards, PhD, ANP-BC, AOCNP
    Nurse Practitioner
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Celgene Corporation, GlaxoSmithKline, Takeda Oncology; Consulting Agreements: Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Takeda Oncology.

    Elizabeth Zerante, MS, AGACNP-BC
    APN Inpatient Hematopoietic Cellular Therapy Service
    University of Chicago Medicine
    Chicago, Illinois

    Speakers Bureau: Cancer Treatment Centers of America.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

    RTP CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Kite, A Gilead Company, and Novartis.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: August 2020
    Expiration date: August 2021

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):